# OnCo record nct03635021 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03635021/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03635021", "NCT03635021" ;
  schema:name "Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumu"@en ;
  schema:alternateName "CR-SEQUENCE"@en ;
  schema:description "A phase 3 trial of panitumumab and bevacizumab (glioblastoma use) in colorectal cancer, run by Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), active but no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03635021/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03635021> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/panitumumab/>, <https://onco.cc/drugs/bevacizumab-glioma/> ;
  onco:companies <https://onco.cc/companies/amgen/> .